The thyroid hormones T4 (thyroxine) and T3 (triiodothyronine) constitute an endocrine system in which signal stability results from the cooperation between glandular production, plasma transport, peripheral conversion and intracellular regulation of bioavailability. The thyroid secretes mainly T4, which acts as a circulating and tissue reservoir, whereas a large proportion of T3, which is more potent at the receptor level, is generated locally within tissues through deiodination. Consequently, the “thyroid signal” does not correspond to a single blood value, but to the amount of T3 available within the nuclei of target cells, as determined by membrane transporters, deiodinases and nuclear receptors.
Iodothyronine physiology is one of the clearest examples of integration between organ endocrinology and molecular biology. Intrathyroidal synthesis requires active iodide uptake, colloidal compartmentalization, controlled oxidative processes and iodine recycling; systemic metabolism depends on selenoenzyme deiodinases that can activate or inactivate the signal, also generating reverse T3 (rT3); biological action occurs mainly through thyroid hormone receptors and transcriptional regulation, but also includes rapid non-genomic mechanisms. On this page, T3 and T4 are analyzed throughout their entire functional pathway, from biosynthesis to tissue-specific regulation of their action.
The thyroid system is organized according to a division-of-labor model. The thyroid predominantly produces T4, a more stable iodothyronine with a longer half-life, whereas the main effector at the receptor level is T3, which has greater affinity for thyroid hormone receptors and greater biological potency. This strategy maintains a stable baseline signal suitable for regulating slow processes such as basal metabolism, growth and maturation, while simultaneously allowing tissues to modulate signal intensity locally through the conversion of T4 into T3.
From an endocrinological perspective, thyroid hormone action is therefore intrinsically compartmentalized. Blood carries a hormonal reservoir, but the final effect depends on how much hormone enters cells, how it is converted and how it interacts with receptors and transcriptional coregulators. This property explains why two individuals with similar free thyroxine (FT4) values may differ in peripheral thyroid hormone action and why, in some systemic conditions, the profiles of free triiodothyronine (FT3) and rT3 may change even when the thyroid gland itself is not primarily affected.
A further level of control is provided by pathways that inactivate the signal. Conversion toward rT3 and inactive deiodinated metabolites represents a mechanism through which the body can reduce thyroid hormone action at the tissue or systemic level. This balance between activation and inactivation is crucial during energy adaptation and systemic illness, when reduced T3 availability may represent an integrated response to metabolic stress.
Three principles explain why thyroid hormone signaling is stable in the blood but flexible within tissues:
This conceptual architecture explains why understanding thyroid physiology requires beginning with intrathyroidal biosynthesis. The manner in which the gland produces and releases iodothyronines, and the way it recycles iodine and precursors, determines the availability of the T4 reservoir that will subsequently be processed by peripheral tissues.
T3 and T4 synthesis occurs within the thyroid follicles and requires a sequence of integrated processes. The first step is the uptake of iodide from the blood through the sodium-iodide symporter (NIS), located on the basolateral membrane of the thyrocyte. This is an active transport process coupled to the sodium gradient maintained by sodium-potassium adenosine triphosphatase (Na+/K+-ATPase), and it is a quantitative determinant of biosynthetic capacity. NIS expression and activity are stimulated by thyroid-stimulating hormone (TSH), thereby linking substrate availability to regulation of the thyroid axis.
Once inside the thyrocyte, iodide must reach the apical pole before being transferred into the follicular lumen. This step involves apical transporters, including pendrin, which contributes to iodide efflux into the colloid. The follicular lumen is a functional extracellular compartment containing thyroglobulin, which is secreted by thyrocytes and acts as the matrix for iodination of tyrosine residues and for the coupling reactions that generate iodothyronines. Compartmentalization is essential because it confines potentially harmful oxidative reactions within a controlled space separated from the interstitium.
The key enzyme involved in oxidation and organification is thyroid peroxidase (TPO), which catalyzes iodide oxidation and iodine incorporation into the tyrosine residues of thyroglobulin, generating monoiodotyrosine (MIT) and diiodotyrosine (DIT). TPO requires hydrogen peroxide, which is produced near the apical pole by dedicated enzymatic systems, particularly oxidase complexes that use nicotinamide adenine dinucleotide phosphate (NADPH). This highlights a crucial aspect of thyroid physiology: thyroid hormone synthesis is an oxidation-intensive process that requires control mechanisms to limit local oxidative stress and preserve function without causing tissue damage.
Once MIT and DIT have been formed, coupling occurs. Two DIT molecules generate T4, whereas the coupling of DIT with MIT generates T3. These reactions also take place on the thyroglobulin matrix within the colloidal compartment. The thyroid therefore does not store free hormones, but hormones incorporated into a macromolecule that forms an intraglandular reserve. This reserve stabilizes hormonal output: the gland can maintain secretion even when iodine intake fluctuates over the short term and can modulate output by altering mobilization of the stored material.
Mobilization occurs through endocytosis of colloid. The thyrocyte internalizes portions of iodinated thyroglobulin into vesicles that merge with lysosomal compartments, where proteolysis releases T4 and T3. The hormones are then secreted from the basolateral pole into the circulation. At the same time, uncoupled MIT and DIT are deiodinated by intracellular enzymes and the iodine is recycled. Recycling is essential for system efficiency and explains how the thyroid can maintain homeostasis even when iodine intake is suboptimal.
Finally, biosynthesis is modulated by iodine autoregulation. An acute increase in iodine availability can temporarily reduce organification, thereby limiting hormone production and preventing excess synthesis. The gland may subsequently escape from this inhibition and restore biosynthesis by adapting to the new substrate level. These mechanisms connect environmental exposure, nutrition and thyroid physiology and provide the basis for understanding clinical phenomena associated with iatrogenic or environmental iodine loads.
The thyroid predominantly secretes T4 and a smaller amount of T3. The proportion is not fixed and depends on thyrotropic stimulation, iodine availability and functional status. Under stimulation, the gland can increase the efficiency of colloid mobilization and, within certain limits, modify the composition of its hormonal output. However, the decisive physiological feature is that most circulating T3, and particularly most intracellular T3 within target tissues, is derived from T4 conversion.
The contribution of peripheral conversion makes thyroid hormone regulation a distributed process. Organs such as the liver and kidneys contribute substantially to systemic T3 production, whereas other tissues, including the brain and skeletal muscle, primarily regulate local availability according to their specific requirements. This model maintains a stable T4 reservoir while allowing T3 to be regulated more dynamically and in a tissue-specific manner. It also explains why thyroid hormone profiles may change significantly during systemic illness without proportional changes in TSH.
This distribution of control has an important consequence: the thyroid ensures continuity and reserve, but the intensity of hormone action is determined by the ability of tissues to generate T3 and protect themselves from excess through inactivation. Understanding this process requires consideration of plasma transport and the availability of free hormone fractions, because the proportion accessible to tissues depends on the balance between protein binding and cellular transport.
In the blood, T4 and T3 are largely bound to plasma proteins, primarily thyroxine-binding globulin (TBG), transthyretin and albumin. Protein binding has an essential physiological function: it creates a large circulating reservoir and buffers fluctuations, making thyroid hormone signaling stable and continuous. The free fraction represents a numerically small but functionally central proportion because it can cross capillary barriers, be transported across cell membranes and become available for conversion and receptor binding.
The equilibrium between bound and free hormone is dynamic. Changes in binding protein concentrations may alter total hormone levels without significantly changing the free fraction, thereby explaining discrepancies between total T4 and FT4. From a physiological perspective, this confirms that the body does not use total hormone concentration as the direct signal, but instead relies on the free fraction and tissue bioavailability. The system is designed to preserve homeostasis of hormone action by maintaining a protein-bound reservoir that ensures continuity even when production varies over the short term.
Differences in protein binding also contribute to distinct biological pharmacokinetics. T4 is more strongly protein-bound and has a longer half-life, consistent with its function as a prohormone. T3 has a shorter half-life and different binding characteristics, permitting more rapid regulation and making it more dependent on conversion and inactivation. These properties are fundamental for understanding the time required for the thyroid axis to reach a new equilibrium and for interpreting transient changes under physiological and pathological conditions.
Plasma transport alone, however, does not ensure tissue action. Iodothyronines must enter cells, and this uptake is mediated by specific transporters. This step represents a crucial control point in thyroid hormone signaling, particularly in tissues such as the brain, where iodothyronine access is tightly regulated.
The intracellular availability of T3 and T4 depends on the expression of membrane transporters. Among the most relevant are monocarboxylate transporter 8 (MCT8) and organic anion transporting polypeptide 1C1 (OATP1C1), which participate in iodothyronine transport within specific tissues. This principle explains why thyroid hormone action is not determined solely by plasma concentrations: the cell controls signal entry and, according to its functional program, can regulate how much iodothyronine enters and how much is subsequently converted into T3.
The role of transporters is particularly evident in the central nervous system. The brain requires tightly regulated access to iodothyronines to support development, myelination and synaptic function. Genetic abnormalities of transport can produce a dissociation between the circulating hormone profile and tissue thyroid status, demonstrating that intracellular bioavailability is the ultimate determinant of hormone action. Even in non-genetic conditions, differences in transporter expression contribute to tissue specificity, with some tissues preferentially using T4 as a substrate for local conversion and others limiting hormone entry as protection against excess.
Cellular uptake is integrated with deiodinase activity. Once inside the cell, T4 may be converted into T3 or directed toward inactivation, and this choice is determined by the combination of deiodinases expressed within the tissue. Transporters and deiodinases therefore create a local endocrine microenvironment in which thyroid hormone action is calibrated according to the biological requirements of each tissue.
A complete understanding of iodothyronine metabolism therefore requires consideration of the deiodinase system and the generation of rT3, because these processes act as biochemical switches that determine the intensity and direction of thyroid hormone signaling.
Deiodinases are selenium-dependent enzymes that catalyze the removal of iodine atoms from the rings of iodothyronines. They represent the main mechanism through which the body controls local activation or inactivation of thyroid hormone signaling. One deiodinase promotes systemic production of T3 from T4 and supports the circulating signal; another contributes to intracellular conversion within key tissues, ensuring local availability; a third directs inactivation by converting T4 into rT3 and T3 into inactive metabolites. This distribution makes conversion a regulatory process rather than a simple chemical reaction.
The balance between activation and inactivation enables adaptation to changing conditions. During energy balance, conversion maintains T3 availability in accordance with metabolic requirements. During systemic stress, inflammation or caloric restriction, inactivation may increase while activation decreases, reducing T3 availability and increasing rT3. This profile is consistent with a strategy aimed at reducing energy expenditure and remodeling metabolism in response to adverse conditions.
Deiodinases therefore function as control mechanisms that create tissue-specific regulation of thyroid hormone action. A tissue may preserve local T3 availability even when systemic production changes, or it may selectively reduce availability to protect itself from excess. This explains why thyroid physiology is resistant to moderate disturbances and why systemic illness may alter thyroid hormone signaling differently across individual tissues.
Iodothyronine metabolism also includes hepatic conjugation pathways and biliary and urinary elimination, which contribute to clearance and enterohepatic recirculation. Although these processes are less central than deiodination in determining signal intensity, they contribute to biological pharmacokinetics and to the stability of the circulating reservoir, integrating the thyroid system with hepatic and renal function.
The next step is to understand how T3 exerts its effects. Its principal action occurs within the nucleus through thyroid hormone receptors that regulate gene transcription by recruiting coactivators and corepressors. This mechanism explains both the widespread metabolic effects of thyroid hormones and the potency of their influence on growth and neurological development.
The classical mechanism of thyroid hormone action is genomic and is mediated by thyroid hormone receptors (TRs), which belong to the nuclear receptor family. Different receptor isoforms have distinct tissue distributions, and this diversity contributes to the specificity of hormone effects. Within the nucleus, receptors bind to regulatory DNA sequences and control the expression of target genes. The presence of T3 changes the state of the receptor complex and determines the recruitment of coregulatory proteins that modulate chromatin structure and transcription.
In the absence of ligand, receptors may associate with corepressors that maintain a transcriptionally repressive state for specific genes. T3 binding induces a conformational change that promotes corepressor dissociation and the recruitment of coactivators, which enhance histone acetylation, chromatin remodeling and transcription. This mechanism makes thyroid hormone action a paradigmatic example of endocrine regulation of gene expression, characterized by high efficiency and effects that develop and consolidate over hours and days.
Genomic effects include the induction of genes involved in mitochondrial biogenesis, the respiratory chain, lipid and glucose metabolism, protein turnover, cardiac function and nervous system development. The physiological consequence is an increase in oxidative capacity and energy consumption, together with remodeling of organ functions, particularly in the cardiovascular and neuromuscular systems. This explains why moderate changes in thyroid hormone signaling can produce complex systemic phenotypes and why the body maintains strict regulation of the thyroid axis.
Tissue specificity depends not only on receptor type, but also on coregulator composition and chromatin context. Different tissues may respond differently to the same T3 availability because they differ in coregulator expression, receptor density and interactions with other endocrine signals. This concept is essential for understanding why thyroid hormone action is not uniform and why certain clinical manifestations are more prominent in specific tissues.
In addition to genomic action, rapid non-genomic pathways contribute to some acute effects and interact with intracellular growth and signaling pathways. These mechanisms do not replace nuclear action but complement it, broadening the temporal spectrum of thyroid hormone effects.
Iodothyronines can activate rapid non-genomic responses through interactions with membrane structures and cytoplasmic signaling pathways. One described mechanism involves interaction with integrin αvβ3, which can activate pathways such as the mitogen-activated protein kinase (MAPK) pathway and other intracellular signaling cascades. These pathways may contribute to rapid effects on vascular function, cellular dynamics and responses to growth signals. From an endocrinological perspective, this means that thyroid hormone signaling can exert effects over short timescales, whereas genomic action consolidates more stable changes through transcriptional regulation.
Non-genomic actions may also modulate sensitivity or responsiveness to concomitant signals, including catecholamines and growth factors, thereby contributing to the complex phenotype of thyroid hormone action, particularly at the cardiovascular and metabolic levels. Integration between rapid and genomic pathways enables multilevel control through immediate responses and long-term remodeling, consistent with the physiological role of iodothyronines in coordinating energy adaptation and organ function.
Overall, the existence of non-genomic pathways broadens the understanding of thyroid hormone signaling without changing its central principle: the final biological effect is determined by the amount of T3 available within target tissues, its interaction with receptors and coregulators and its convergence with other signaling systems. This leads to the final synthesis, which integrates biosynthesis, transport, metabolism and action within a unified framework and clarifies the interpretive limitations of blood hormone values alone.
Thyroid hormone physiology demonstrates that the endocrine signal results from a complex sequence of processes: thyroid production and release, plasma binding, cellular transport, deiodinase-mediated conversion and receptor interaction. Each step can be modulated by energy status, inflammation, hepatic and renal function and systemic conditions, producing biochemical profiles that do not always correspond to the same intensity of tissue signaling. In particular, reduced conversion to T3 and increased production of rT3 during systemic illness demonstrate how the body can remodel the signal without proportionally modifying thyroid hormone production.
The presence of a circulating T4 reservoir and tissue-specific regulation of T3 explain why assessment of thyroid hormone action requires an integrated approach. TSH represents the central sensor of pituitary perception of thyroid hormone signaling, but it does not always correspond to peripheral T3 availability, particularly when tissue metabolism has been remodeled. Similarly, FT4 values represent substrate availability but do not automatically describe the amount of T3 reaching receptors within each tissue.
In conclusion, T3 and T4 define an endocrine system in which stability is ensured by hormonal storage and plasma protein binding, whereas adaptability is provided by transport mechanisms and deiodinases. Genomic action mediated by thyroid hormone receptors accounts for systemic effects on metabolism, growth and development, while non-genomic pathways complete the picture through rapid responses and integration with other signals. This perspective is essential for understanding thyroid disorders, conditions characterized by altered conversion and the biological significance of changes in laboratory parameters within their clinical context.